The incidence of optic neuropathy after stereotactic radiosurgery (SRS) is related to the total dose, fraction size, and treatment volume. Theoretically, fractionated SRS can decrease this risk. In this paper, we report our technique for fractionated SRS and assess its potential role in the management of tumors located adjacent to the anterior visual pathways. Since 1997, thirteen patients (median age: 50, range 21-76) with lesions in close proximity to the anterior visual pathways were treated on the CyberKnife image guided SRS system (Accuray, Inc., Sunnyvale, CA). The CyberKnife is a 6MV linear accelerator mounted on a robotic arm which can monitor and adjust to changes in the target position in real time thus eliminating skeletal frame immobilization and allowing for convenient multi-fraction SRS treatments. Magnetic Resonance Imaging (MRI) and computerized tomography (CT) imaging for treatment planning were obtained with the patient's head immobilized in an aquaplast mask. After image fusion, the target and critical structures were delineated. Two to five fractions were prescribed with approximately a 24-hour interfraction interval. The patients received 25 Gy in 5 fractions (n=5), 21 Gy in 3 fractions (n=5), or 20 Gy in 2 fractions (n=3) to the 75-95% isodose line. Ten of the thirteen patients had good pretreatment vision. In nearly all instances, the volume of the optic nerve that received 80% of the prescribed dose was < 0.05 cm3. In all instances, the volume of the optic nerve that received 50% of the prescribed dose was < 0.5 cm3. Only one patient received more than a 5 Gy daily dose to > 0.03 cm3 of optic nerve. With median follow up of 18 months (range 12 to 54), four patients have had improvement in their vision. No visual deterioration has been observed in any of the other patients. In addition, there has been no tumor progression within the treated field. Fractionated SRS using the CyberKnife is technically feasible and may decrease the risk of optic neuropathy. Greater patient accrual and longer follow up will be necessary to further determine the clinical benefit of this approach.
Introduction
Stereotactic radiosurgery (SRS) has become an alternative to microsurgery and conventional radiation therapy in the treatment of many skull-base lesions. However, tumors located adjacent to the anterior visual pathways (the optic nerves, tracts, and chiasm) are problematic. The surgical morbidity from operating in the orbital apex, chiasmatic cistern, and the adjacent cavernous sinus has been well described (1, 2) . Meanwhile, enthusiasm for using radiotherapy to treat these lesions has been tempered by concern about injury to the optic nerve and uncertain efficacy for some benign lesions. Although optic neuropathy secondary to radiation injury is a well described complication (3), the radiation tolerance of treating only a portion of the optic apparatus is still unknown. Retrospective analyses demonstrate increased complication rates when the optic nerve or optic chiasm receives greater than 50 Gy conventionally fractionated radiotherapy or 8 Gy administered in a single fraction (4-7). Although many radiosurgery centers limit total dose to any portion of the anterior visual pathways to less than 8 Gy, this threshold may not represent the true tolerance of partial treatment of the optic nerve or chiasm. Meanwhile, there is concern that limiting the dose to the optic nerve may compromise effective tumor control.
Fractionated SRS over a short period of time can reduce the daily fraction dose to the optic apparatus and may represent a beneficial compromise, which reduces the risk of optic neuropathy while maintaining a high dose to the tumor. Because most current stereotactic methods use skeletal fixation for immobilization, patient discomfort limits the treatment to a single fraction. Meanwhile, non-invasive frames used for fractionation compromise the accuracy, which can be achieved with standard radiosurgical systems. In addition, most of the current systems use a fixed isocenter, which may result in significant dose inhomogeneity when treating nonspherical lesions. The CyberKnife is a 6MV linear accelerator mounted on a robotic arm which can monitor and adjust to changes in the target position in near real time, thus eliminating the need for skeletal frame immobilization and allowing for convenient multi-fraction SRS treatments. We postulated that the CyberKnife stereotactic treatment system (Accuray, Incorporated, Sunnyvale, CA) would allow for fractionated, short course, high dose SRS for lesions in close proximity to the optic pathways. The CyberKnife's repeated accuracy, high dose conformality, and homogeneity make it ideal to examine the safety and efficacy of this approach. The purpose of this paper is to define our techniques and report our preliminary experience.
Methods and Materials
At Stanford University Medical Center, patients with lesions in proximity to the anterior visual pathways are evaluated in a multidisciplinary setting that includes neurosurgeons, radiation oncologists, neurologists, and neuroradiologists. Thirteen patients had lesions that were located adjacent to or involving the anterior visual pathways. All patients were thought to be suitable for fractionated stereotactic radiosurgery on the CyberKnife system. Because of the experimental nature of the treatment machine and the nonconventional dose and fractionation, all treated patients treated signed a consent form approved by our institution's IRB and the FDA. The patient's clinical characteristics are summarized in Table I . Patients ranged in age from 21 to 74 years. Two patients had received prior conventional radiotherapy.
Another patient had previous SRS (single fraction) to a separate intracranial treatment volume to a dose of 18 Gy.
All of the patients received treatment on the CyberKnife, an image guided radiosurgery system capable of fractionated treatment. This device consists of a lightweight 6MV linear accelerator manipulated by a computer controlled robotic arm, details of which have been previously described (8, 9) . Briefly, the patient is positioned on the treatment table and their head is non-invasively immobilized (using an AquaPlast mask and head holder). A prior CT is performed with the patient similarly immobilized, and either with or without MRI fusion, is used for treatment planning. A digitally reconstructed radiograph of the patient's skull is generated (cranial DRR) from the CT dataset. Throughout treatment, sequential paired digital x-rays of the skull are obtained specifically before each beam is administered. A computer workstation performs rapid image-to-image registration of the acquired images and the skull DRR. Repeatedly during the SRS treatment, the x-ray imaging sys- tem determines the location of the patient and communicates changes to the robot. The robot accounts for small patient movements by automatically realigning the treatment beam with stereotactic precision with accuracy comparable to frame based systems (10).
Dose planning was carried out using CT and MRI imaging. Thin slices (usually 1.25 to 2.0 mm) were obtained through the critical regions for the purposes of treatment planning. The radiation oncologist and the neurosurgeon jointly defined the target volume and the critical structures (eyes, ipsilateral optic nerve, contralateral optic nerve, and chiasm). The secondary collimators used for treatment depended on the lesion size and location (ranged from 7.5 mm to 30 mm). One case was planned using two isocenters, three cases were planned using a single isocenter or nine cases used non-isocentric inverse treatment planning technique (11). Dose volume histograms of the target volume and all outlined structures were produced for every patient. All patients were treated with fractionated SRS using two to five fractions separated by approximately 24 hours. Follow up evaluations which included clinical evaluation, opthomalogic exams, and repeat imaging studies which were performed at 3 months, 6 months, 1 year, and then annually.
Results
Thirteen patients (7 men, 6 women; median age 60 range 21-76) with lesions near the anterior visual pathways were treated with limited fraction high dose radiosurgery using the CyberKnife treatment system. The patient characteristics are listed in Table 1 . Six of the treated tumors were meningioma. Eight patients had previous surgery, two had prior conventional radiotherapy, and one had prior stereotactic radiosurgery. Nine patients suffered from some pre-treatment visual disturbance. Ten patients had good pretreatment vision (defined as better than 20/60). The treating radiation oncologist and neurosurgeon determined the fractionation schedule based on the size and volume of the treated tumor, dose to the optic nerve and optic chiasm, length of optic nerve subject to radiation and patient's baseline visual acuity. In each case, the stereotactic radiosurgical treatment was fractionated. The characteristics of each individual treatment and follow up information are listed in Table II . Five patients received the dose in 5 fractions, five patients received 3 fractions, and three patients received 2 fractions.
There was approximately 24 hours between treatment fractions. The treatment was well tolerated by all patients. Treatment volume ranged from 1.2 to 21 cm3. The maximum and minimum daily dose that the tumor, ipsilateral optic nerve, contralateral optic nerve, and chiasm received are shown in Table III . In most patients, the daily dose to the critical structures was less than 5 Gy. In only one instance, the maximum daily dose to the optic nerve exceeded 8 Gy. The maximum dose the contralateral optic nerve experienced was ≤ 5 Gy in all but one patient. The volume of critical structures (ipsilateral and contralateral optic nerve, and chiasm) that received varying percent of daily treatment doses is listed Table IV . In nearly all instances, the volume of the optic nerve that received 80% of the prescribed dose was < 0.05 cm3. In all instances, the volume that received 50% of the prescribed dose was ≤ 0.5 cm3.
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Only one patient received more than a 5 Gy daily dose to greater than 0.03 cm3 of optic nerve. 
Discussion
In this report, we demonstrate that the CyberKnife stereotactic radiosurgery system is capable of delivering short course fractionated SRS for lesions in close approximation to the anterior visual pathways. The technique allows the delivery of a high dose of radiation to the tumor with a rapid decline in dose to the adjacent critical structures. By fractionating the treatment, we potentially reduced the radiation dose to below the threshold for optic nerve injury. In addition, we were able to decrease the volume (length) of the optic apparatus that received higher dose. The rapid decline in dose achieved by predominantly non-isocentric radiosurgical crossfiring resulted in minimal actual dose delivered to the sensitive structures. Ten patients with good pretreatment vision (better than or equal to 20/60 in the affected eye) were considered to be at high risk for ipsilateral visual injury and raised concerns about the dose delivered to the entire optic apparatus (optic nerve, optic chiasm, and contralateral optic nerve). Three additional patients had already lost ipsilateral vision, but we remained quite con-cerned about limiting dose to the nearby optic chiasm and contralateral optic nerve. All patients tolerated the fractionated SRS without any acute toxicity.
With follow up range 12 -54 months (median 18 months), none of the ten patients with good pretreatment visual acuity have experienced any visual deterioration in the ipsilateral eye. In addition, none of the thirteen patients experienced visual deterioration in the contralateral eye. The amount of time necessary for optic nerve injury to manifest after stereotactic radiosurgery is not known. The time to injury may be dependent on the total dose and the volume of optic nerve treated. The presentation of optic nerve injury often occurs within a few months after treatment and most instances probably manifest by one-year post-radiosurgery. Based on the reported literature almost 80% of the cases occurred within 18 months of the treatment, but a few cases were reported to occur much later (3, 5, 6, 7, 11, 12) . While our series is small and follow up is short, this paper demonstrates that the CyberKnife radiosurgery system can deliver high dose fractionated radiosurgery for these lesions and in the short term appears to be safe. Longer follow up and more patients are necessary to fully determine the late optic complications if any, with this treatment approach.
It has been suggested from retrospective reviews that the tolerance of the optic nerve and chiasm to traditional fractionated external beam radiotherapy is 50-55 Gy (6). Most centers attempt to keep the dose to any part of the optic nerve or optic chiasm below 45 to 50 Gy. Delayed injury to the anterior visual pathways is a well-documented complication of conventional external beam radiation therapy. Review of the literature supports a consistent clinical profile of radiation optic neuropathy. Patients present with the acute onset of visual loss. Neuroimaging is essential in the diagnosis of radiation optic neuropathy, both to exclude tumor recurrence and to detect typical radiographic changes. On magnetic resonance imaging (MRI), optic neuropathy is characterized by high contrast enhancement within the optic nerve on gadolinium enhanced T1 weighted imaging. Fraction size and total dose are important parameters in the development of optic neuropathy. Parsons and colleagues described retrobulbar optic neuropathy in 12 optic nerves from 131 patients. The mean and median times of onset were 47 and 28 months, respectively. Interestingly, no optic nerve injuries were noted in 106 optic nerves that received less than 59 Gy (6). Young et al. reported on two cases of optic neuropathy and in both cases the optic nerve and chiasm had received between 55 and 62 Gy (13). The experience has been similar from institutions that use particle beam therapy. In one series of 274 patients treated with conventionally fractionated particle beam therapy the rate of optic nerve injury was 4.4% (11 patients). The injury was apparent 7 to 40 months after treatment with a median time to injury of 12 months. The injured patients received a maximum dose to the optic apparatus of between 50.2 to 69.6 GyEq, with a median dose of 59.43 GyEq (14). Goldsmith and colleagues reviewed various dose and fractionation schemes, and proposed a new nominal standard dose term, the optic ret, to differentiate between safely employed radiation therapy regimens and those with a risk for radiation optic neuropathy. The optic ret is a formula used to define isoeffects for dissimilar treatment regimens, accounting for the fraction size and fraction number. Based on a review of the reported cases of optic nerve injury and the UCSF clinical experience with conventional external beam treatment, they defined the optic nerve tolerance to be 890 optic ret (4).
In contrast to radiation optic neuropathy due to conventional radiotherapy, there are few reports of visual loss after stereotactic radiotherapy. Leber et al. retrospectively ana-lyzed the optic nerve toxicity after a single fraction gamma knife radiosurgery in fifty patients treated for a variety of tumors (15). The actuarial incidence of optic neuropathy was 0, 26.7, and 77.8% in patient cohorts who received radiation doses <10 Gy, 10 to 15 Gy, and >15 Gy, respectively to the optic pathways. The authors assumed that the dose the optic nerve received was less than or equal to the marginal dose in the patients with benign tumors because of displacement of the nerve by tumor. Some have criticized this assumption because in some cases these tumors encase the optic nerve (16). In those instances, the dose to the optic nerve could have significantly been underestimated. In a series of 34 patients who underwent gamma knife radiosurgery for cavernous sinus meningiomas, three patients developed visual complications after treatment (1). The estimated doses to the optic nerve were 7, 10.5, and 12 Gy, respectively. Tishler reported on 52 patients who received single fraction radiosurgery to the cavernous sinus, 4 patients developed optic neuropathy (7). All four patients had received greater than 8 Gy in a single fraction whereas the 17 patients who received a lesser dose had no obvious deterioration. Some criticize this report because the imaging resolution was inadequate for precise visualization of the optic nerve (16). Based on these collective experiences, many centers have adopted a single fraction of 8 Gy as the tolerance of the optic nerve to a single fraction of radiosurgery. In contrast to this, the Mayo Clinic argues persuasively that the tolerance may in fact be 50-100% higher. In a recently published series of 88 patients treated with gamma knife radiosurgery no patients experienced visual complications. The radiosurgery dose to the optic nerve apparatus was between 1 and 16 Gy (median 10 Gy) and in 59 cases the dose to the visual pathways was ≥ 8 Gy (16).
The tolerance of the optic nerve to radiotherapy may actually depend on a number of factors (3). Certainly, the total dose and the fraction size are important determinants of injury to the optic nerve. The volume of the optic nerve treated may also be an important consideration. Prior radiotherapy, chemotherapy, or surgery may lower the threshold dose necessary for optic nerve damage. Patients who are planned on modern and sophisticated systems that incorporate MRI imaging may be less likely to suffer an injury than patients treated on systems that use CT based planning alone (3).
The trepidation that treating physicians have when they approach the optic apparatus is in part explained by the relative ineffectiveness of repair mechanisms within this structure. Although high dose corticosteriods, and hyperbaric oxygen have been used, they are without any reproducible success (3). No beneficial therapy for radiation-induced optic neuropathy has been established. However, in many instances observation alone (non-treatment) of lesions around or near the optic apparatus is also associated with sig-nificant risk. These lesions can extend and involve the optic chiasm, the contralateral optic nerve, and the pituitary. Visual loss secondary to tumor progression is a real risk, and in the case of pituitary tumors, intratumoral hemorrhage may result in sudden irreversible visual loss. In the current series, many patients selected for treatment had already manifested progressive symptoms and serial-imaging studies revealed disease progression.
Because of this irreversible nature of this particular complication, we sought to investigate whether short course high dose fractionated stereotactic radiosurgery would be feasible. The advantages of fractionating radiotherapy are well known and form the basis for conventional radiotherapy (17). Fractionation allows the normal tissues adequate time for repair of sub-lethal damage and at the same time, fractionation increases the probability of tumor control because the inter-fraction interval allows for reoxgenation and reassortment of tumor cells into radiosensitive phases of the cycle. Recent laboratory studies on rats have demonstrated that these same radiobiological principles apply to fractionated SRS. In fact, rats with 9L gliosarcomas of the brain treated with fractionated SRS were substantially less likely to experience visual pathway damage (18). Short course high dose fractionated SRS treatments can realize similar biological effectiveness as single fraction treatments. The biological equivalent dose (BED) of these fractionation schemes is between 35 -40 Gy, which is equivalent to 14-16 Gy given in a single fraction treatment. This dose has been shown adequate for slow proliferating conditions such as acoustic neuromas, meningiomas, and pituitary adenomas.
Recent clinical studies using a comparable dose and fractionation regimen have demonstrated that fractionated radiosurgery for acoustic neuromas may result in equivalent tumor control and better hearing preservation (19).
The principle reason that SRS has previously been administered as a single fraction is the patient discomfort associated with skeletal immobilization. Some centers have developed frames that rely on dental molds and/or bony prominences to anchor an external frame of reference to the head and can be reattached without difficulty (20, 21) . These systems, which by their very nature depend on patient cooperation, may be prone to increased set up errors and the reproducibility of set up remains questionable. The CyberKnife system with its localizing x-ray system and direct feedback to the treatment unit allows for precise treatment without the need for rigid immobilization. This clinical experience being reported takes advantage of this technical capability. These preliminary results show that fractionated schemes may be effective for tumor control without associated injury to the optic system. More patients and longer follow up will be needed to make a definitive statement of the partial optic nerve/chiasmal tolerance with this fractionation scheme. At this point, these new fractionation schemes remain a subject of investigation and should not be considered the standard of care. Patients should be encouraged to participate in IRB approved prospective studies of thoughtful, and new approaches to difficult clinical situations.
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